Antony C. Mattessich
President and CEO at Ocular Therapeutix Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Ocular Therapeutix Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Aura Biosciences Inc. June 20, 202485.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | Aura Biosciences Inc. | Grant or award | +15,000 | — | — |
| Jun 17, 2025 | Aura Biosciences Inc. | Grant or award | +13,000 | — | — |
| Jun 20, 2024 | Aura Biosciences Inc. | Grant or award | +10,500 | — | — |
| Feb 5, 2024 | Ocular Therapeutix Inc. | Open-market sale | +19,642 | $4.86 | $95,460 |
| Feb 3, 2024 | Ocular Therapeutix Inc. | Grant or award | +180,400 | — | — |
| Jan 31, 2024 | Ocular Therapeutix Inc. | Open-market sale | −18,338 | $4.95 | $90,773 |
| Aug 30, 2023 | Ocular Therapeutix Inc. | Open-market purchase | +6,500 | $3.81 | $24,765 |
| Feb 6, 2023 | Ocular Therapeutix Inc. | Open-market sale | −19,669 | $4.24 | $83,397 |
| Jan 30, 2023 | Ocular Therapeutix Inc. | Grant or award | +176,300 | — | — |
Questions about Antony C. Mattessich
What boards is Antony C. Mattessich on?
Antony C. Mattessich sits on the boards of Aura Biosciences Inc. and Ocular Therapeutix Inc.
What company is Antony C. Mattessich the CEO of?
Antony C. Mattessich is President and CEO of Ocular Therapeutix Inc.
How long has Antony C. Mattessich served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.